Literature DB >> 3745389

Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine.

H Ehrsson, S Eksborg, A Lindfors.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3745389     DOI： 10.1016/s0378-4347(00)83648-8

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  9 in total

Review 1.  Not too little, not too much-just right! (Better ways to give high dose melphalan).

Authors:  P J Shaw; C E Nath; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2014-08-18       Impact factor: 5.483

2.  Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.

Authors:  Georgia M Beasley; Jonathan C Riboh; Christina K Augustine; Jonathan S Zager; Steven N Hochwald; Stephen R Grobmyer; Bercedis Peterson; Richard Royal; Merrick I Ross; Douglas S Tyler
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

3.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.

Authors:  G M Beasley; A P Coleman; A Raymond; G Sanders; M A Selim; B L Peterson; M S Brady; M A Davies; C Augustine; D S Tyler
Journal:  Ann Surg Oncol       Date:  2012-05-02       Impact factor: 5.344

5.  A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.

Authors:  Georgia M Beasley; Ketan Sharma; Joyce Wong; Mike Miller; Ryan S Turley; Michael Lidsky; Melanie Masoud; Mark W Dewhirst; Paul J Mosca; Jonathan S Zager; Douglas S Tyler
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

6.  Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.

Authors:  Gina Shetty; Georgia M Beasley; Sara Sparks; Michael Barfield; Melanie Masoud; Paul J Mosca; Scott K Pruitt; April K S Salama; Cliburn Chan; Douglas S Tyler; Kent J Weinhold
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

7.  Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

Authors:  N McMahon; T Y Cheng; G M Beasley; I Spasojevic; W Petros; C K Augustine; P Zipfel; J C Padussis; G Sanders; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2009-01-30       Impact factor: 5.344

8.  Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.

Authors:  H Ehrsson; S Eksborg; A Osterborg; H Mellstedt; A Lindfors
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

9.  Intratumoral measurement and plasma pharmacokinetics of intravenously administered melphalan. Report of a patient with plasmacytoma.

Authors:  S Friberg; H Ehrsson; S Eksborg; C Carenfeldt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.